Inflammatory Diseases Research
Research in the Centre for Inflammatory Diseases (CID) spans basic experimental biology, clinical research and clinical practice in inflammatory diseases.
Heart disease is the number one killer in our community. The underlying basis of it is the thickening of arteries by the pathological process of atherosclerosis; an occlusive disease of arteries that causes heart attacks and strokes.
White blood cells are central to the development of severe forms of human glomeraula inflammation. They are also increasingly recognised as important in acute kidney (renal) injury, a common complication of hospital stays that increases the chance of a poor clinical outcome.
Type 2 diabetes is a metabolic syndrome is caused by the development of insulin resistance, which is normally a consequence of chronic obesity.
Leukocytes play critical roles in protective responses to infection and injury. However, these same cells are also major contributors to inappropriate, injurious responses in inflammatory diseases.
Liver fibrosis and cirrhosis is the common end stage to all liver diseases in humans. We study mechanisms of liver fibrosis and factors that determine its progression to cirrhosis.
The Infectious Diseases Research Group conducts a wide range of basic, clinical and translational research and quality assurance activities.
Inflammation is one of the first responses of the immune system to infection or injury. Our laboratory uses cutting edge in vivo imaging techniques to directly visualise and study the immune processes involved in inflammation in both infectious and non-infectious models.
The Regulatory T Cell Therapies lab focusses on generating autoantigen-specific regulatory T cells to treat autoimmune diseases.